Skip to main content
Hong Zheng, MD, Oncology, Hershey, PA

HongZhengMD

Oncology Hershey, PA

Hematologic Oncology

Physician

Dr. Zheng is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Zheng's full profile

Already have an account?

  • Office

    500 University Dr
    H088
    Hershey, PA 17033
    Phone+1 717-531-6585
    Fax+1 717-531-0429

Education & Training

  • Yale-New Haven Medical Center
    Yale-New Haven Medical CenterFellowship, Hematology and Medical Oncology, 2010 - 2013
  • Penn State Milton S Hershey Medical Center
    Penn State Milton S Hershey Medical CenterResidency, Internal Medicine, 2007 - 2010
  • Capital University of Medical Sciences
    Capital University of Medical SciencesClass of 1995

Certifications & Licensure

  • PA State Medical License
    PA State Medical License 2007 - 2024
  • CA State Medical License
    CA State Medical License Active through 2013
  • American Board of Internal Medicine Hematology
  • American Board of Internal Medicine Medical Oncology

Publications & Presentations

PubMed

Abstracts/Posters

  • Long-Term Follow-up of Hematopoietic Stem Cell Transplantation with the Modified Peking Regimen for the Treatment of Acute Leukemia
    Hong Zheng, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • Maintenance Decitabine (DAC) Improves Disease-Free (DFS) and Overall Survival (OS) after Intensive Therapy for Acute Myeloid Leukemia (AML) in Older Adults, Particular...
    Hong Zheng, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • Graft-Versus-Host Disease Causes the Failure of Donor Hematopoietic Progenitor Cells to Reconstitute Plasmacytoid Dendritic Cells That Promote Tolerance of Donor T Cel...
    Hong Zheng, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019

Lectures

  • Effect of Avelumab to Immune Response in AML: A Phase I Study of Avelumab in Combination with Decitabine As First Line Treatment of Unfit Patients 
    61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
  • Multi-Dimensional Analysis of Immune Signature Predicts Response to Decitabine Treatment in Elderly Patients with AML 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

  • Cost-Effectiveness of Different Surgical Treatment Approaches for Early Breast Cancer: A Retrospective Matched Cohort Study from China
    Cost-Effectiveness of Different Surgical Treatment Approaches for Early Breast Cancer: A Retrospective Matched Cohort Study from ChinaFebruary 2nd, 2021
  • Researchers Discover a Potential Biomarker for AML Relapse After Stem Cell Transplant
    Researchers Discover a Potential Biomarker for AML Relapse After Stem Cell TransplantSeptember 24th, 2015